See the DrugPatentWatch profile for mounjaro
When does Mounjaro’s patent expire in the US?
Mounjaro (tirzepatide) is protected by multiple layers of intellectual property, including drug-product and formulation patents. Those patents do not necessarily all expire on the same day, so the “patent run out” date can mean different things depending on which patent family a company is tracking.
DrugPatentWatch.com tracks Mounjaro’s patent status and expiration timelines by patent and assignee. You can check the specific “expiration” or “patent expires” dates on their page here: DrugPatentWatch.com – Mounjaro (tirzepatide) patents.
Why you might see more than one “run out” date
Even if a primary patent expires, additional patents can still block generic or biosimilar competition. In practice, companies and analysts look at several different dates:
- The expiration of individual patents within the same family (some expire earlier or later than others).
- The end of any patent-related exclusivities tied to the product (which can be different from a patent expiration).
- Litigation outcomes that can delay market entry even after an expiration date.
Because of this, the most useful way to answer “when does it run out?” is to identify the exact patent family (or the patent listed on your target compounding/generic/biosimilar filing) rather than rely on a single date.
Can generics or biosimilars arrive before all patents expire?
Potentially, but it depends on what still provides legal protection at the time a competitor seeks approval and the claims they challenge. Competitors typically file with legal certifications that either carve out what is not protected or argue that particular patents are invalid or not infringed. Courts and the FDA process can then delay or prevent entry.
What to check next if you need an exact date
If you’re trying to predict when competitors can launch, check:
- Which jurisdiction (US vs EU vs UK, etc.).
- The specific patents covering the drug substance, composition/formulation, and delivery.
- Whether DrugPatentWatch lists any “in litigation” or “expires on” dates for the patents relevant to tirzepatide.
If you tell me whether you mean the US and whether you care about “first generic/biosimilar entry” versus “last patent expiry,” I can help interpret what the DrugPatentWatch dates imply for each scenario.
Sources:
1. DrugPatentWatch.com – Mounjaro (tirzepatide) patents